Tourmaline Bio, Inc. (TRML) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Tourmaline Bio, Inc.

TRML

NASDAQ

Unprofitable

Unprofitable

437M

Biotechnology

Next Earning date - 13 Mar 2025

437M

Biotechnology

Next Earning date - 13 Mar 2025

13.83USD

0.74 ( 5.65%)

After-hours 15.89$

2.06 (14.93%)

Market Closed (as of Feb 14, 21:00 EDT)

Relative Strenght

7

Volume Buzz

-9%

Earning Acce

No

Dist 52w H.

70%

Quote Panel

Updated March 13, 2025

1W 18.50 % 1M 23.21 % 3M -22.90 % 1Y -59.16 %

Key Metrics

Market Cap
436.95M
Shares Outstanding
25.64M
Share in Float
16.01M
Dividende
0

Earning Date
13 Mar 2025
Price Target
17.04
Average Volume
270412
Beta
2.3705313

Range
11.87-46.36
Industry
Biotechnology
Website
https://www.tourmalinebio.com
Sector
Healthcare

Fundamentals

Relative Strength

TRML

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$8M

18650%

2025-Revenue

$3.51

-275%

2025-EPS

0

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

42.00(146.48%)

Number of analyst

1

Last analyst upgrade/downgrade

Wedbush

initialise

Previous: Not converted

2025-03-06

Now: Outperform

BMO Capital

initialise

Previous: Not converted

2024-12-05

Now: Outperform

Cantor Fitzgerald

initialise

Previous: Not converted

2024-10-15

Now: Overweight

Earnings Growth

YoY

Current

Estimates

Q4.22

N/A

-0.00
vs -3.48

Q1.23

N/A

-0.37
vs -4.40

Q2.23

N/A

-0.20
vs -0.00

Q3.23

N/A

-1.64
vs -0.00

Q4.23

N/A

-0.81
vs -0.00

Q1.24

N/A

-0.55
vs -0.37

Q2.24

N/A

-0.68
vs -0.20

Q3.24

N/A

-0.78
vs -1.64

Q4.24

N/A

-0.86
vs -0.81

Q1.25

N/A

-0.87
vs -0.55

Sales Growth

YoY

Current

Estimates

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

2.3M vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Return on Equity

QoQ

Q1.23

-5%

-0.05
vs 0

Q2.23

+38%

0.38
vs -0.05

Q3.23

-5%

-0.05
vs 0.38

Q4.23

+1%

0.01
vs -0.05

Q1.24

-4%

-0.04
vs 0.01

Q2.24

-5%

-0.05
vs -0.04

Q3.24

-6%

-0.06
vs -0.05

Q4.24

-7%

-0.07
vs -0.06

Institutionnal Ownership

QoQ

Q4.23

54

54
vs NA

NA

Q1.24

105

105
vs 54

94%

Q2.24

86

86
vs 105

-18%

Q3.24

92

92
vs 86

7%

Q4.24

102

102
vs 92

11%

Earnings Growth

Latest News

TRML

globenewswire.com

7 hours ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

TRML

globenewswire.com

7 hours ago

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

TRML

globenewswire.com

7 hours ago

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

TRML

globenewswire.com

7 hours ago

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

TRML

globenewswire.com

7 hours ago

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

TRML

globenewswire.com

8 hours ago

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day